Atara Shares Sink After FDA Stalls Cancer Treatment
Atara Biotherapeutics shares plunged after the FDA rejected its application to bring a blood cancer treatment to market. Shares of the biotechnology company were recently down 46.5% to $7.04. The ...
Atara stock plummets on FDA setback for EBV drug
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) tumbled 51% after the company disclosed receiving a Complete Response ...
What foods have red dye 3 in them? And what is the difference with red dye 40?
By reading labels and staying informed, people can reduce their exposure to potentially harmful additives like red dye 3 ...
Why Red 3 food dye is now banned in the US, and how to spot it on food and medicine labels
Substance that gives confectionery, cakes, cherries and more a bright red hue was banned from cosmetics after being linked to ...
Supreme Court case offers Trump path to dismantle Obamacare mandates
The Supreme Court will hear a challenge to Obamacare’s preventive care mandates, giving Trump a chance to reshape rules on ...
Narsoplimab shows promise in reducing mortality for TA-TMA patients
Corporation (NASDAQ: OMER), a biotechnology company with a market capitalization of $515.75 million, today reported results ...
Targeted Oncology52m
FDA Approves Axatilimab for Chronic GVHD in New Vial Sizes
Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...